MedTrace Logo

Prevention of Breast Cancer-related Lymphedma With Tacrolimus

NCT04390685 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-06-25

No results posted yet for this study

Summary

Breast cancer-related lymphedema is one of the most common and feared consequences of breast cancer treatment. Tacrolimus ointment may prevent lymphedema by inhibition of CD4+T cells.

Conditions

  • Lymphedema

Interventions

DRUG

Tacrolimus ointment

Treatment with tacrolimus ointment once daily for one year following axillary lymph node dissection

Sponsors & Collaborators

  • Odense University Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-26
Primary Completion
2022-09-30
Completion
2022-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04390685 on ClinicalTrials.gov